Features include always present findings: Focal segmental glomerulosclerosis, Podocyte foot process effacement, and Steroid-resistant nephrotic syndrome. 4 total HPO annotations.

DAAM2 encodes dishevelled associated activator of morphogenesis 2 (1,068 aa). Key regulator of the Wnt signaling pathway, which is required for various processes during development, such as dorsal patterning, determination of left/right symmetry or myelination in the central nervous system. Highest expression in Esophagus Muscularis (162.0 TPM) and Brain Spinal cord cervical c-1 (147.2 TPM).

Nephrotic syndrome, type 24 is associated with mutations in the DAAM2 gene on chromosome 6.

DAAM2 is classified as a druggable target with score 0.0.

Genetic testing for DAAM2 is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for nephrotic syndrome, type 24 has been reported in the published literature.

Phenotype severity distribution: 3 always present features.

Estimated prevalence: Unknown (Unknown prevalence).

No clinical trials have been registered for nephrotic syndrome, type 24.

39 publications have been identified in PubMed for nephrotic syndrome, type 24. Research spans Case Report / Case Series (35%), Epidemiology / Natural History (27%), and Review / Meta-Analysis (14%).